A PHASE 1B/2A MULTICENTER OPEN-LABEL DOSEESCALATION STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND EFFICACY OF CC-220 MONOTHERAPY AND IN COMBINATION WITH OTHER TREATMENTS IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA

Go Back to All Clinical Trials

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Other Inclusion Criteria:

1) Patients must ha e a documented diagnosis of MM and have measurable disease defined as; a. M-proteln (serum and or urine protein electrophoresis (sPEP or uPEP)): sPEP >0.5 g dL or uPEP 200 mg/24 hours and or b. Light chain MM without measurable disease in the serum or urine: serum immunoglobulin free light chain 10 mg/dL (100 mg/L) and abnormal serum immunoglobulin kappa lambda free light chain ratio 2) All Patients must have disease that is relapsed/refractory to 2-3 lines of therapy including IMiDs, bortezomib, and/or immunotherapy. 3) All Patients must have received prior treatment with at least 2 consecutive cycles of a proteasome inhibitor or a proteasome inhibitor-containing regimen

1) Patient has nonsecretory or oligosecretory multiple myeloma. 2) Patients with Plasma Cell leukemia or amyloidosis. 3) Patients with gastrointestinal disease that may significantly alter the absorption of CC-220. 4) Patient has received any of the following within the last 1 days of initiating IP: a) Plasmapheresis b) Major surgery (as defined by the Investigator) c) Radiation therapy other than local therapy for MM associated bone lesions d) Use of any systemic myeloma drug therapy